Key facts
- It has raised $16.8M; the latest was Accelerator/Incubator in May 2024.
- Notable investors include Tiny Supercomputer Investment Company, Cherry Ventures, IQ Capital Partners, Hoxton Ventures, MSD Global Health Innovation Fund — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Baseimmune
- ·The full record, as it builds
Funding rounds
No funding rounds for Baseimmune are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Baseimmune
Developer of a platform designed for pathogen analysis to create antigen and vaccine designs. The company's platform is based on a technology that can generate antigens using a level of informatics depth to tackle emerging and challenging pathogens, enabling healthcare providers to ensure the vaccines remain effective even if a pathogen mutates.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2019
- Employees
- 28
- Website
- baseimmune.co.uk/
- Ownership
- Privately Held (backing)
Baseimmune doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Baseimmune shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Baseimmune in its N-PORT filings yet. We sweep new filings monthly.